Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity.

Once-weekly retatrutide improved WOMAC knee pain more than placebo in adults with painful knee osteoarthritis and obesity, with differences up to -1.83 at 68 weeks.

• Why it matters: Painful knee osteoarthritis in people with obesity is a major unmet need, and retatrutide’s triple GIP/GLP-1/glucagon receptor activity may offer a dual benefit for pain and weight.
• What they did: In two phase 3 trials (TRIUMPH-4 and TRIUMPH-1-OA), adults without diabetes (BMI ≥27) were randomized to retatrutide (9 or 12 mg; or 4, 9, or 12 mg) or placebo, with WOMAC pain assessed at 68 or 80 weeks using hybrid-treatment estimands.
• The result: At 68 weeks in TRIUMPH-4, hybrid-treatment WOMAC pain changes were -3.96 (9 mg) and -3.74 (12 mg) versus -2.12 with placebo (differences -1.83 and -1.61), and retatrutide also reduced body weight more than placebo.

AI summary of the abstract · may contain errors · not medical advice · read the paper.